Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 1
2018 4
2019 6
2020 4
2021 8
2022 6
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted.
Mancini M, Monaldi C, De Santis S, Papayannidis C, Rondoni M, Sartor C, Bruno S, Pagano L, Criscuolo M, Zanotti R, Bonifacio M, Tosi P, Arock M, Valent P, Cavo M, Soverini S. Mancini M, et al. Among authors: bruno s. Biomark Res. 2023 Mar 10;11(1):29. doi: 10.1186/s40364-023-00468-7. Biomark Res. 2023. PMID: 36894973 Free PMC article.
Lessons Learned from the Development and Roll-Out of the rVSVΔG-ZEBOV-GP Zaire ebolavirus Vaccine to Inform Marburg Virus and Sudan ebolavirus Vaccines.
Coller BG, Lapps W Jr, Yunus M, Bruno S, Eichberg MJ, Lee AW, Liu K, Drury R, Millogo J, Macareo LR, Armstrong TH, Blue JT, Isopi LA, Hughes M, VanRheenen SM, Deutsch J, Tell JG, Dubey SA. Coller BG, et al. Among authors: bruno s. Vaccines (Basel). 2022 Sep 1;10(9):1446. doi: 10.3390/vaccines10091446. Vaccines (Basel). 2022. PMID: 36146524 Free PMC article. Review.
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors.
Mancini M, De Santis S, Monaldi C, Castagnetti F, Lonetti A, Bruno S, Dan E, Sinigaglia B, Rosti G, Cavo M, Gugliotta G, Soverini S. Mancini M, et al. Among authors: bruno s. Front Oncol. 2022 Aug 5;12:901132. doi: 10.3389/fonc.2022.901132. eCollection 2022. Front Oncol. 2022. PMID: 35992847 Free PMC article.
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia.
Soverini S, De Santis S, Martelli M, Monaldi C, Castagnetti F, Gugliotta G, Papayannidis C, Mancini M, Bruno S, Venturi C, Machova Polakova K, Ernst T, Maar D, Corner A, Cavo M. Soverini S, et al. Among authors: bruno s. Leukemia. 2022 Sep;36(9):2250-2260. doi: 10.1038/s41375-022-01660-8. Epub 2022 Jul 30. Leukemia. 2022. PMID: 35908105
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia.
Bruno S, Bandini L, Patuelli A, Robustelli V, Venturi C, Mancini M, Forte D, De Santis S, Monaldi C, Grassi A, Chiurumbolo G, Paolini S, Cristiano G, Papayannidis C, Sartor C, Nanni J, Ottaviani E, Curti A, Cavo M, Soverini S. Bruno S, et al. Front Oncol. 2021 Sep 30;11:728613. doi: 10.3389/fonc.2021.728613. eCollection 2021. Front Oncol. 2021. PMID: 34660293 Free PMC article.
31 results